Global Fund investments:

2014-2016 Allocation period
- Tuberculosis disbursements: $25.9m
- TB/HIV disbursements: $6.59m
- RSSH disbursements: $4.35m

2017-2019 Allocation period
- Tuberculosis disbursements: $13.3m
- TB/HIV disbursements: $6.44m

Domestic – National Health Accounts, funding request submitted to the Global Fund; External – country reported, OECD DAC CRS

Detailed financial gap analysis reported by country based on Global Fund Modules

Uganda FINANCES: What resources were available to support the national program in the past six years? And what resources are available in the coming three years?

Historical investments by funding source (2012-2017)

- In 2015-2017, 50% of NSP need was funded.

TB financing¹

Planned investments by funding source and intervention (2018-2022)²

OUTCOME: How many people received the treatment and prevention services that they need?

Global Fund Results (2018)
- People with TB treated: 55.4k
- People with drug-resistant TB on treatment: 489
- HIV+ TB patients on ART: 21.4k

IMPACT: What is the trend among people who continue to fall ill or die? (actual and hypothetical in the absence of program)

TB deaths (excluding HIV+): 60% increase from 2012 to 2017
67% increase from 2000 to 2017

TB case finding and treatment coverage

TB treatment outcomes

Preventative TB therapy for HIV+